1. (original): A crystalline polymorph B of 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 13.2 (vs), 10.7 (s), 8.8 (m), 6.4 (m), 5.87 (s), 5.75 (m), 5.35 (m), 5.26 (m), 4.87 (m), 4.66 (s), 4.40 (m), 3.86 (m), 3.79 (m), 3.66 (m), 3.60 (m), 3.57 (m), 3.52 (m), 3.45 (m), 3.40 (m), 3.36 (m), 3.27 (m), 3.18 (m), 2.95 (m), 2.72 (m), 2.65 (m); wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity.

2. (original): A crystalline polymorph B of 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride having an X-ray powder diffraction pattern substantially as depicted in figure 2.

3. (original): A crystalline polymorph B of 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride having an X-ray powder diffraction pattern substantially as depicted in figure 3.

4. (original): An amorphous form of 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride.

5. (currently amended): An amorphous form of 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride according to claim 4 having a powder X-ray diffraction pattern substantially as depicted in Figure 4.

6. (original): A process for the preparation of a crystalline polymorph according to claim 1, wherein an aqueous solution of hydrochloride is added to a solution of the free base 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride in an organic solvent.

7. (currently amended): A process according to claim 6, wherein the organic solvent is a C_3-C_{10}ketone, C_3-C_{10}acetate, C_2-C_{10}nitrile, C_1-C_{10}alcohol or C_2-C_{10}ether, or a mixture ~~mixtures~~ thereof.

8. (original): A process for the preparation of a crystalline polymorph according to claim 1, wherein a suspension of Form A or the amorphous form 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-

2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride is stirred in an organic solvent.

9. (currently amended): A process according to claim 8, wherein the organic solvent is a C_3-C_{10}ketone, C_3-C_{10}acetate, C_2-C_{10}nitrile, C_1-C_{10}alcohol or C_2-C_{10}ether, or a mixture ~~mixtures~~ thereof.

10. (currently amended): A process according to claim ~~8 or 9~~, wherein the organic solvent is selected from the group consisting of acetone, 1-butanol, 2-butanol, butyl actetate, tert- butylmethyl ether, cumene, dimetylsulfoxide, ethanol, ethylether, ethylformiate, heptane isobutylacetate, isopropyl acetate, methylacetate 3-methyl-1-butanol~~,~~ and methylethyl ketone.

11. (currently amended): A process according to claim ~~8 or 9~~, wherein the organic solvent is selected from the group consisting of acetone, methyl ethyl ketone; ethylacetate, isopropylacetate, acetonitrile, isopropylalcohol, methyl-tert.butyl ether and THF.

12. (currently amended): A process according to ~~any of claims 8 to 11~~claim 8, wherein the organic solvent contains small amounts of water.

13. (original): A process according to claim 12, wherein the amount of water is 0.1 to 15% by volume of the suspension of 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride.

14. (original): A process according to claim 13, wherein the amount of water is 0.5 to 10% by volume of the suspension of 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride.

15. (original): A process for the preparation of a crystalline polymorph according to claim 1 wherein a suspension of Form A or the amorphous form of 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride is stirred in water.

16. (currently amended): A process according to ~~any of claims 6 to~~ claim 15, wherein 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride is isolated by filtration and dried in air or vacuum.

17. (currently amended): A process ~~according to any of claims 6 to 16~~ for the preparation of a crystalline polymorph according to claim 1, wherein seeding is carried out with crystals of the crystalline polymorph according to claim 1.

18. (currently amended): A process for the preparation of the amorphous form according claim ~~4 or 5~~, wherein a solution 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride in an organic solvent or in water is evaporated to dryness.

19. (original): A process according to claim 18, wherein the organic solvent is a C_3-C_{10}ketone.

20. (currently amended): A process according to claim ~~18 or~~ 19, wherein the organic solvent is acetone.

21. (original): A process for the preparation of crystalline polymorph Form A of 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride, wherein a concentrated solution of 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride in an organic solvent is mixed with a non-solvent.

22. (original): A process according to claim 21, wherein the organic solvent is an C_1-C_{10}alcohol, tetrahydrofuran, N-methylpyrrolidone or N,N-dimethylformamide and the non-solvent is a C_4-C_{12}alkane or C_1-C_{10}acetate.

23. (currently amended): A process according to claim ~~21 or~~ 22, wherein a solution of 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride in a C_1-C_4alcohol is mixed with heptane.

24. (currently amended): A process according to ~~any of claims 21 to 23~~ claim 21, wherein seeding with crystals of the Form A of 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride is carried out.

25. (currently amended): A pharmaceutical composition comprising an effective amount of a crystalline polymorphic form of 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride according to ~~one of claims~~ claim 1 ~~to 3 or the amorphous form according to claims 4 or 5~~, and a pharmaceutically acceptable carrier.

26. (new): A process according to claim 6, wherein 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]-amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride is isolated by filtration and dried in air or vacuum.

27. (new): A pharmaceutical composition comprising an effective amount of the amorphous form of 3-[[(1S)-1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid monohydrochloride according to claim 4, and a pharmaceutically acceptable carrier.